Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight

NCT02313220 on ClinicalTrials.gov · last registry update 2016-11-17

A small phase 2 — 50 participants, against a typical 110. The sponsor logged completion for March 2016. Primary outcome, as filed: Body weight (kg). exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Uppsala University
Sponsor type: Other
Enrollment: 50
Started: 2014-12
Primary completion: 2016-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Body weight (kg)

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.